Tatyana Zharikova

Tatyana Zharikova

I.M. Sechenov First Moscow State Medical University, Russia

Title: Russia’s landscape in regenerative medicine


Tatyana Zharikova did her Residency at the Department of Surgery from 2010-2011, second Residency (2011-2013) and PhD (2016) at the Department of Urology of the I.M. Sechenov First Moscow State Medical University. She is a Research Fellow of the Research Institute for Uronephrology and Reproductive Health. She is also a Research Fellow of the Institute for Regenerative Medicine (IRM) and became Deputy Director of the Institute for Regenerative Medicine (IRM) in 2017.


The main goal of regenerative medicine (RM) is to restore damaged organs and tissues using molecular, cell and tissue engineering approaches. In this aspect, RM can be presented as a part of the new world health care paradigm (translational and personalized medicine), which dedicates to optimize healthcare system using novel products all around the world. Being a member of the international community, the Russian Federation (RF) is involved in this process. The aim of this presentation is to critically evaluate the regenerative medicine state in the Russian Federation in the movement of the global changes. In the RF, private investors, government and the Russian Academy of Science have a particular interest in RM. From 2010, first-rate public funds, who support fundamental (RFBR) and fundamental-applied researches (RSF), regularly finance cutting-edge scientific projects in this field. To date, there is an annual double increase in quantity of publications related to RM in the RF. The main RM areas in Russia concern the application of mesenchymal and induced stem cells in bone tissue and vessel regeneration. There are number of research groups, who investigate neural tissue, liver and pancreas regeneration. Regenerative and reconstructive urology requires a special attention because first operations on urethra restoration using tissue engineered constructs were carried out on humans. To create a legal framework in the field of RM, the government passed the law on cell products in 2017. Thus, RM is intensively developing in Russia now. However, unbiased problems (insufficient financial support, low level of international collaborations, low publication activity and innovation passivity) still exist. The solution of them will determine the further development of this promising field in Russia.